Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution?

Area of Science:

• Gastroenterology and Immunology
• Pharmacology and Therapeutics

Background:

• Inflammatory Bowel Disease (IBD) encompasses chronic conditions like Crohn's disease and ulcerative colitis.
• Current IBD treatments often involve monotherapy with biologics or small molecules.
• Advanced Combination Treatment (ACT) combines therapies with distinct mechanisms of action.

Purpose of the Study:

• To review existing evidence on the efficacy and safety of ACT in IBD.
• To evaluate preclinical data, real-world evidence, and randomized controlled trials (RCTs) of ACT.

Main Methods:

• Narrative review of scientific literature.
• Systematic review of randomized controlled trials assessing ACT in IBD.
• Analysis of preclinical studies and real-world data.

Main Results:

• Systematic review of RCTs indicates ACT significantly improves clinical outcomes in IBD patients.
• No significant safety concerns were identified in the reviewed RCTs.
• Variability in trial design and outcome measures necessitates standardization efforts.

Conclusions:

• ACT demonstrates compelling efficacy for IBD management.
• Challenges include standardizing treatment protocols and ensuring long-term safety.
• Current clinical use is off-label, requiring careful patient-specific consideration and future biomarker-guided trials.